Domestic anti-lung cancer drug gefitinib is launched and the financial burden on patients is reduced
[China Pharmaceutical Network Product Information] Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor, suitable for the treatment of patients who have previously received chemotherapy or are not suitable for chemotherapy. It is an urgently needed clinical drug for locally advanced or metastatic non-small cell lung cancer. It is reported that as a major scientific and technological project for the creation of new drugs in my country’s “Twelfth Five-Year Plan”, the domestically produced first-line targeted drug gefitinib (Erico) for the treatment of non-small cell lung cancer, successfully developed by Qilu Pharmaceutical over a period of 6 years, was officially launched on the 18th. It breaks the monopoly of foreign pharmaceutical giants in the Chinese market, and while enhancing the accessibility of medicines, it will significantly reduce the financial burden of medicines on patients.
(The domestic anti-lung cancer drug gefitinib is on the market and the financial burden on patients has been reduced. Picture source: Baidu Pictures)
The domestic anti-lung cancer drug gefitinib is on the market
It is understood that lung cancer is one of the most common malignant tumors, among which non-small Cell lung cancer accounts for the majority of lung cancer. Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor, suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has previously received chemotherapy or is not suitable for chemotherapy. It is an urgently needed clinical drug with specific effects.
Gefitinib was first successfully developed by an American pharmaceutical company and launched in China in 2005. However, due to its exclusive monopoly by foreign pharmaceutical companies, the price of gefitinib in the domestic market has been high for a long time. Stay high.
It is understood that the launch of domestically produced gefitinib has broken the exclusive monopoly of foreign pharmaceutical giants in the Chinese market and greatly lowered the market price of the product, which means that non-small cell lung cancer Treatment has truly entered an era of affordability.
At the same time, the Lung Cancer MDT Expert Committee was formally established on the 18th, which will bring domestic lung cancer treatment into the era of multidisciplinary joint diagnosis and treatment model, and is expected to greatly improve the level of lung cancer diagnosis and treatment in our country.
Qilu Pharmaceutical has long been focused on the research and development of high-level new drugs, with the aim of continuously increasing the accessibility of medicines to patients, so that people can afford and cure diseases.
“Pharmaceuticals are about curing diseases and saving lives. We always regard ‘making the best medicine to express our love’ as our corporate mission and strive to practice it. Qilu people understand ‘good medicine’ It is based on the belief of loyalty to drug quality and adhering to the concept that “one millionth of a company is 100% of the patient’s” to make drugs safer; it uses the latest technical means to make drugs more effective and cheaper, so that patients can use their drugs more safely. The experience is more humane and more dignified!” said Ms. Li Yan, general manager of Qilu Pharmaceutical.
The launch of domestically produced gefitinib (Irico) broke the market monopoly of foreign original research products, reducing the price of the drug from the initial 5,000 yuan per box to less than 2,000 yuan, which can counteract the high price The complete replacement of gefitinib will greatly reduce the financial burden on patients.
